Table 2.
Somatic Mutations Identified in Plasma by Digital NGS
| Case | Sex | Age, y | Study group | Stage | dNGS reactions, n | KRAS (dNGS score) | GNAS (dNGS score) |
|---|---|---|---|---|---|---|---|
| 45 | M | 62 | Disease control | NA | 384 | p.G12D (7) | p.R201H (11) |
| 49 | M | 77 | Disease control | NA | 192 | p.G12V (3) | |
| 64 | F | 66 | PDAC + IPMN | IA | 384 | p.G12D (7) | |
| 65 | M | 44 | PDAC + IPMN | IIB | 192 | p.G12D (18) | |
| 67 | M | 64 | PDAC + ITPN | IIB | 384 | p.G12V (94) | |
| 70 | M | 76 | PDAC | IV | 384 | p.G12V (15) | |
| 73 | M | 50 | PDAC | IV | 374 | p.G12D (17) | |
| 77 | F | 66 | PDAC | IB | 384 | p.G12V (4) | |
| 82 | M | 54 | PDAC | IV | 384 | p.G12R (45) | |
| 84 | F | 66 | PDAC | IV | 384 | p.G12V (8) | |
| 86 | F | 75 | PDAC | IIB | 384 | p.G12D (12) | |
| 93 | F | 48 | PDAC | IIB | 384 | p.G12D (25) | |
| 94 | F | 66 | PDAC | IV | 384 | p.G12D (5) | |
| 96 | M | 61 | PDAC | IV | 384 | p.G12D (47) | |
| 98 | F | 59 | PDAC | IV | 192 | p.G12D (21) | |
| 100 | M | 89 | PDAC | IB | 384 | p.G12V (4) | |
| 101 | M | 55 | PDAC | IB | 384 | p.G12D (72)/p.G12V (7) | |
| 105 | F | 69 | PDAC | IIB | 241 | p.G12D (50) | |
| 115 | F | 67 | PDAC | IV | 384 | p.G12D (21)/p.G12V (7) | |
| 118 | M | 80 | PDAC | IA | 384 | p.G12D (8)/p.G12V (8) | |
| 120 | F | 68 | PDAC | IIA | 384 | p.G12D (7) | |
| 123 | F | 69 | PDAC | IIB | 384 | p.G12D (9) | |
| 125 | F | 68 | PDAC | IA | 384 | p.G12D (6) | |
| 126 | M | 89 | PDAC | IV | 384 | p.G12D (63) | |
| 127 | M | 65 | PDAC | IA | 384 | p.G12D (5) |
F, female; M, male; dNGS, digital next-generation sequencing; IPMN, intraductal papillary mucinous neoplasm; ITPN, intraductal tubulopapillary neoplasm; NA, not applicable; NGS, next-generation sequencing; PDAC, pancreatic ductal adenocarcinoma.